(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) slid by a staggering 10.28% to $3.89 at 15:09 EST on Thursday, following the last session’s downward trend. NASDAQ is jumping 1.79% to $12,708.02, after two successive sessions in a row of losses. This seems, as yet, an all-around bullish trend exchanging session today.
TherapeuticsMD’s last close was $4.33, 62.96% below its 52-week high of $11.69.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $1.88.
PE Ratio
TherapeuticsMD has a trailing twelve months price to earnings ratio of 2.07. Meaning, the purchaser of the share is investing $2.07 for every dollar of annual earnings.
Sales Growth
TherapeuticsMD’s sales growth is negative 91.2% for the present quarter and negative 93.7% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TherapeuticsMD’s stock is considered to be overbought (>=80).
Moving Average
TherapeuticsMD’s value is higher than its 50-day moving average of $3.79 and way under its 200-day moving average of $5.84.
Earnings Before Interest, Taxes, Depreciation, and Amortization
TherapeuticsMD’s EBITDA is -3.69.
More news about TherapeuticsMD (TXMD).
